Compared with pan-JAK inhibitors such as tofacitinib, the JAK1 selectivity of UPA may reduce off-target effects; however, safety concerns remain, including an increased risk of herpes zoster (particularly in Asian populations), liver enzyme abnormalities, and potential cardiovascular events. The gene discussed is JAK1; the disease is herpes zoster.